<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815945</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-GYN 7</org_study_id>
    <nct_id>NCT00815945</nct_id>
  </id_info>
  <brief_title>Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors</brief_title>
  <official_title>Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MSD SHARP &amp; DOHME GmbH (formerly Essex Pharma GmbH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AGO Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterine sarcomas account for less than 5% of all carcinomas of the uterine corpus. The
      prognosis of these patients is extremely limited. Recurrence rates of 50-60% are reported
      even for early-stage disease (FIGO I/II). Median overall survival is below 12 months in
      patients with advanced or metastatic disease.

      Ovarian carcinosarcoma is extremely rare among ovarian malignancies (&lt; 2%). That is why there
      is insufficient data as a basis for establishing a gold standard. As a result, these cases
      tend to be treated in the same way as uterine sarcomas or epithelial ovarian malignancies in
      clinical practice.

      On the basis of data published to date on the treatment of mixed mesenchymal-epithelial
      tumors, it is clear that the treatments commonly used to date have limited activity while
      producing clinically relevant toxicity. The regimes verified so far (Cisplatin / Ifosfamide,
      Ifosfamide/Paclitaxel and Gemcitabine/Docetaxel) exhibit a considerable side effect spectrum
      and are only rarely feasible on clinical everyday life conditions, so e. g. the rate of
      withdrawals due to toxicity was in a study collective of selected females treated with the
      last combination at 40 %. The physician has to check in every individual case if one of the
      above mentioned combinations is feasible. The search for alternative effective and better
      tolerated treatment options is essential. The toxicity data on the carboplatin-PLD
      combination are known, and efficacy has been identified in small cohorts.

      The objective of this study is to explore the efficacy of combination PLD-carboplatin
      treatment in a larger patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study in patients with mesenchymal or mixed epithelial mesenchymal tumors of the ovary
      or uterus is designed as a prospective single-arm, open - label, multicenter phase II study
      to evaluate the efficacy of PegLiposomal Doxorubicin and Carboplatin combination
      chemotherapy.

      40 patients will be recruited to receive PegLiposomal Doxorubicin (PLD) in a continuous i. v.
      infusion of at least 60 minutes at a dose of 40 mg/m2 on Day 1, followed by a 30-minute i. v.
      carboplatin infusion according to AUC 6 (formula devised by Calvert et al).

      Patients will get outpatients treatment. At screening the patients' eligibility will be
      assessed, their baseline and demographic characteristics obtained, and baseline values for
      the effect variables collected. Patients with measurable lesions, non-measurable lesions or
      histological documentation will be included into this trial. Measurable lesion and
      non-measurable lesions will be documented by x-ray, ultrasound, computed tomography or MRI.

      The patients' safety will be monitored during therapy until recovery of toxicities.

      In patients with measurable lesions at baseline, the (post)-treatment values for effect
      according to the RECIST criteria will be collected as shown in table 6. CR, PR and SD have to
      be confirmed by a repeat measurement after an interval of at least four weeks.

      Follow-up is scheduled every three months during the first two years after the end of
      treatment.

      As from year 3 the follow-up takes place outside the study in the context of general
      aftercare.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anticancer activity in terms of progression-free survival time (PFS)</measure>
    <time_frame>every 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability, i.e. type, frequency, severity and duration of adverse reactions (CTCAE,Version 3.0)</measure>
    <time_frame>until recovery of toxicities</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticancer activity in patients with measurable or evaluable disease in terms of response rates (CR, PR, SD, PD) according to RECIST criteria</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of tumor marker CA-125 with imaging methods</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Mesenchymal Tumor</condition>
  <condition>Carcinosarcoma</condition>
  <condition>Leiomyosarcoma</condition>
  <arm_group>
    <arm_group_label>PegLiposomal Doxorubicin + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive PegLiposomal Doxorubicin (40mg/m²) and Carboplatin (AUC6) every 28 days. Treatment period up to 6 months (therapy can be continued in case of tumor response and benefit for the patient)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegLiposomal Doxorubicin</intervention_name>
    <description>PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months</description>
    <arm_group_label>PegLiposomal Doxorubicin + Carboplatin</arm_group_label>
    <other_name>Caelyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months</description>
    <arm_group_label>PegLiposomal Doxorubicin + Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented mesenchymal or mixed epithelial-mesenchymal tumor of the
             ovary or uterus

          -  Patients with a primary diagnosis of FIGO I-IV uterine carcinosarcoma and optimum
             debulking (postoperative residual tumor &lt; 1cm) may be enrolled only if
             cisplatin-ifosfamide combination therapy is not feasible.

          -  Patients with metastatic uterine carcinosarcoma may be enrolled only if
             Ifosfamide/Paclitaxel combination therapy is not feasible.

          -  Patients with metastatic leiomyosarcoma may be enrolled only if gemcitabine-docetaxel
             combination therapy is not feasible.

          -  Measurable (target lesion) tumor, evaluable (non-target lesion) tumor or histological
             documentation

          -  No more than one prior chemotherapy. Any prior platinum or anthracycline- containing
             chemotherapy must have been completed more than 6 months previously

          -  Prior radiotherapy ≤ 25% of the hematopoietic system is allowed provided it took place
             more than 6 weeks before recruitment

          -  Patients are allowed to have received prior anticancer hormone therapy or specific
             immunotherapy. Patients must have completed these therapies at least three weeks
             before recruitment to the study

          -  All women with a theoretical possibility of pregnancy must produce a negative
             pregnancy test (serum or urinary) within seven days before starting treatment

          -  General health of 0 - 2 on the ECOG score

          -  At least 18 years of age

          -  Estimated life expectancy above 12 weeks

          -  At least 3 weeks since major surgery

          -  Appropriate hematologic, renal and hepatic function in accordance with the following
             definitions:

          -  Absolute neutrophil count (ANC) ≥ 1.5 × 109 /l

          -  Platelets ≥ 100 × 10 9/l

          -  Total bilirubin ≤ 1.25 times upper limit of normal

          -  Estimated GFR ≥ 50 ml/min

          -  LVEF &gt; 50 %

          -  Informed consent must be obtained from all patients.

        Exclusion Criteria:

          -  More than one prior chemotherapy (or radiochemotherapy)

          -  Active infection or other serious medical impairment liable to affect the patient's
             ability to receive treatment according to protocol.

          -  Administration of other chemotherapy drugs or other anticancer hormone treatments
             during the study.

          -  History of clinically manifest atrial or ventricular arrhythmia (&gt; LOWN II) and
             congestive heart failure, even if controlled by drugs (NYHA class &gt; II). Documented
             myocardial infarction within 6 months before study enrollment.

          -  Pregnant or breastfeeding women, or women not practicing appropriate birth control
             methods

          -  Participation in another study using experimental drugs within the last 30 days

          -  Any other conditions or therapies which the physician believes might put the patient
             at risk or impair the study objective.

          -  Known hypersensitivity to carboplatin or pegylated liposomal doxorubicin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Harter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Essen Mitte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité, Campus Virchow Klinikum, Frauenklinik</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus, Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Bonn</city>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH, Frauenklinik</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Düsseldorf, Frauenklinik</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Frauenklinik</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe-Universität, Klinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynäkologisch-onkologische Praxis</name>
      <address>
        <city>Hannover</city>
        <zip>30177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Kliniken AG, Frauenklinik</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen und Marburg GmbH, Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern, Frauenklinik</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Frauenklinik</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Universitätsfrauenklinik</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst Schmidt Kliniken GmbH, Klinik für Gynäkologie und gynäkologische Onkologie</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2008</study_first_submitted>
  <study_first_submitted_qc>December 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2008</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leiomyosarcoma</keyword>
  <keyword>carcinosarcoma</keyword>
  <keyword>mixed epithelial mesenchymal tumor</keyword>
  <keyword>endometrial stroma sarcomas</keyword>
  <keyword>Müllerian mixed tumors</keyword>
  <keyword>carcinosarcoma of the uterus</keyword>
  <keyword>mesenchymal tumors of the ovary or uterus</keyword>
  <keyword>mixed epithelial mesenchymal tumors of the ovary or uterus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Carcinosarcoma</mesh_term>
    <mesh_term>Mixed Tumor, Mullerian</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

